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Abstract
Purpose: To evaluate the clinical efficacy and toxicity of stereotactic body radiation therapy (SBRT) using
extracranial gamma knife in patients with mainly bulky inoperable early stage non-small cell lung carcinoma
(NSCLC).
Materials and methods: A total of 43 medically inoperable patients with mainly bulky Stage I/II NSCLC received
SBRT using gamma knife were reviewed. The fraction dose and the total dose were determined by the radiation
oncologist according to patients’ general status, tumor location, tumor size and the relationship between tumor
and nearby organ at risk (OAR). The total dose of 34~47.5 Gy was prescribed in 4~12 fractions, 3.5~10 Gy per
fraction, one fraction per day or every other day. The therapeutic efficacy and toxicity were evaluated.
Results: The median follow-up was 22 months (range, 3-102 months). The local tumor response rate was 95.35%,
with CR 18.60% (8/43) and PR 76.74% (33/43), respectively. The local control rates at 1, 2, 3, 5 years were 77.54%,
53.02%, 39.77%, and 15.46%, respectively, while the 1- and 2-year local control rates were 75% and 60% for tumor
≤3 cm; 84% and 71% for tumor sized 3~5 cm; 55% and 14.6% for tumor sized 5~7 cm; and 45%, 21% in those
with tumor size of >7 cm. The overall survival rate at 1, 2, 3, 5 years were 92.04%, 78.04%, 62.76%, 42.61%,
respectively. The toxicity of stereotactic radiation therapy was grade 1-2. Clinical stages were significantly important
factor in local control of lung tumors (P = 0.000). Both clinical stages (P = 0.015) and chemotherapy (P = 0.042)
were significantly important factors in overall survival of lung tumors.
Conclusion: SBRT is an effective and safe therapy for medically inoperable patients with early stage NSCLC. Clinical
stage was the significant prognostic factors for both local tumor control and overall survival. The toxicity is mild.
The overall local control for bulky tumors is poor. Tumor size is a poor prognostic factor, and the patients for
adjuvant chemotherapy need to be carefully selected.
Background
About 20% to 30% of patients with non-small cell lung
cancer (NSCLC) are diagnosed with early stage NSCLC
[1,2]. Surgery is the standard treatment of NSCLC
patients, but radiation therapy is the only chance to cure
T1-T2 tumors if patient is not eligible for surgery or
refuses it [3-7]. Radiotherapy (RT) can offer an alternative
therapy in these cases, but the outcome with conventional
RT is unsatisfactory [1,5,8-10]. However, in recent years,
there are enthusiasms for stereotactic body radiation ther-
apy (SBRT) centering on the observation that small- to
medium-sized tumors can be eradicated with a noninva-
sive therapy because of the considerable effect, and several
prospective clinical results from trials using SBRT have
been published [2,7,11-15]. Since large tumor size was
reported to be a predictor of poor outcome of lung cancer
by many studies [7,16,17], we try to evaluate the efficacy
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NSCLC who had accepted the SBRT in our institution.
Methods
Patient population and characteristics
Forty-three patients with mainly bulky early stage
NSCLC pathologically confirmed by percutaneous lung
biopsy, phlegmy cytology or fiberoptic bronchoscopy
were treated using SBRT with the body gamma knife
system from June 2000 to October 2008. The patient
characteristics are summarized in Table 1. The Clinical
staging system of lung cancer (UICC 2009 version) was
adopted for this study [18]. In these 43 patients, 33
patients were considered not to be candidates for surgi-
cal resection after evaluation by thoracic surgeon
because of comorbidities such as cardiovascular disease,
chronic obstructive pulmonary disease and diabetes. The
others refused surgical resection.
Radiotherapy equipment
Patients were treated using the stereotactic gamma-ray
whole-body therapeutic system (body gamma-knife)
developed by OUR International Technology & Science
Co., Ltd. (Shenzhen, China). The body gamma knife
uses rotary conical surface focusing to focalize 30 Co-60
sources with total activity of 8500 Ci, the focal dose rate
at the initial source setting was 3 Gy/min. The body
gamma knife consists of a radiation source, collimator,
and treatment bed. The head of radiation source is an
iron ball rind with 30 Co-60 sources scattered through-
out the cavity of the primary collimator. The source
body rotates horizontally around the central axis with
the 30 bundles of gamma ray directed toward a focal
target. In the present study, three groups of chamber
with collimator aperture diameters of 3 mm, 12 mm,
and 18 mm, respectively, were used; the full width at
half-height of the dose-field range at the target was 10
mm, 30 mm, and 50 mm, respectively. As the aperture
diameter of the collimator decreased, the density of the
distributed dose increased, and the periphery dose
decreased. Three groups of terminal collimators with
different apertures direct the focusing of the radials.
Target volume of 1-10 cm in diameter could be treated
using a combination of collimators with different aper-
ture diameters. Finally, the treatment bed can move in
X, Y, and Z directions and can automatically adjust the
target to the focal point of the radials.
Treatment planning and delivery
Supine or prone position was selected according to diag-
nostic chest CT scan, and each patient could keep the
posture for 30 minutes. All patients were immobilized
using a stereotactic body frame with a vacuum pillow to
create reproducible immobilization. Abdominal clamping
pressure was applied using a diaphragm control device.
The planning CT was scanned with 3 mm slice through-
out the tumor, and 5 mm slice in other areas of the
thorax and upper abdomen. After the scan was finished,
the positional parameters were recorded in order to
repeat the position when the patient was irradiated. The
images of CT simulation were then imported into the
treatment planning system (OUR WB-GR TPS99).
Reconstructions were performed on a three-dimensional
conformal radiotherapy planning algorithm. The Dose-
Volume Histogram (DVH) was used to calculate V20
(percent volume of total lung receiving 20 Gy) and the
doses of other OARs. The gross tumor volume (GTV)
was the primary tumor. The clinical target volume (CTV)
was identical to GTV. The planning target volume (PTV)
was created using pulmonary window which allowed a
1 . 0c mm a r g i na r o u n dt h eC T V .Ar a d i a t i o nd o s ew a s
prescribed to the 50% isodose line. Three-dimensional
imaging of isodose coverage of GTV and PTV was used
to select aperture diameter, the number and location of
target iso-center depended on the size and shape of the
target volume. The total dose was between 34 and 47.5
Gy (at 50% isodose line) which represents between 56
and 80 Gy calculated in BED10(biological equivalent)
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equal to 10 for the tumor. The median value of BED at
the isocenter (at 100% isodose line) was 193.2 Gy (range,
184.8~201.6 Gy) in 4 patients with tumor size of ≤3c m ,
194.8 Gy (range, 142.8~240.0 Gy) in 24 patients with
tumor size of 3~5 cm, 165.5 Gy (range, 142.8~212.2 Gy)
in 10 patients with tumor size of 5~7 cm and 144.0 Gy
(range, 142.8~184.8 Gy) in 9 patients with tumor size of
>7 cm.
T h es t r a t e g yw a st oa c h i e v ead o s ev o l u m ec o n s t r a i n t
for lung of V20 Gy <35%, a maximal dose < 50 Gy of
the BED to the esophagus and < 45 Gy to the spinal
cord. Radiotherapy was delivered over 1~2 weeks. 4
patients had received prophylaxis irradiation of the med-
iastinum with doses of 40~46 Gy in 20~23 fractions, of
which 3 patients had stage T2b, 1 patient had stage T3.
Chemotherapy
13 patients had received 2~4 cycles chemotherapy with
NVB (25 mg/m
2, d1,d8) and DDP (75 mg/m
2,d 1 ,r e p e a t e d
every 3 weeks). In these 13 patients, 1 patient was staged
T1b (≤ 3 cm), 5 patients staged T2a (3~5 cm), 4 patients
staged T2b (5~7 cm) and 3 patients staged T3 (> 7 cm).
The mean age of the patients was 69 years (range 46~76).
6 of the patients had co-morbidities.
Evaluation of therapeutic efficacy and toxicity
The short-term therapeutic effects of local tumor control
was classified as complete response (CR), partial response
(PR), stable disease(SD), or progressive disease(PD) as
judged according to CT image. According to Response
Evaluation Criteria in Solid Tumors (RECIST) (WHO
2000 version) [19], a CR was defined as complete disap-
pearance of all measurable disease for 4 weeks, a PR was
defined as a 50% reduction in the sum of the perpendicu-
lar diameters of all measurable lesions for 4 weeks, and
PD was defined as a 25% increase in the sum of the per-
pendicular diameters of all measurable lesions and new
lesions that developed for 4 weeks. Patients whose disease
did not meet the criteria for either a PR or progressive dis-
ease were classified as having stable disease for 4 weeks.
Overall efficacy consisted of CR and PR evaluated at four
weeks after treatment was finished.
The major indexes of long-term effects were survival
and local control. Local recurrence was judged accord-
ing to chest CT image, PET-CT image, or biopsy. The
time of local control was defined as the duration from
the beginning date of SBRT to the date of local recur-
rence. The time of survival was duration from the
beginning date of SBRT to the date of follow-up for sur-
viving patients or to the date of death.
The radiation reaction was classified as early or late
adverse effects in lung, skin, esophagus and bone mar-
row according to NCI-CTC 3.0 version [20]. The early
adverse effects were defined to occur within the first 90
days after the beginning date of SBRT, and the late
adverse effects occur beyond the first 90 days after the
beginning date of SBRT.
Follow-up
T h ef o l l o w - u pd u r a t i o nw a sd e f i n e da st h et i m ef r o m
the beginning date of SBRT to the last date of follow-up
for surviving patients or to the date of death. The last
date of follow-up was in June 30th, 2009. The median
duration of follow-up was 22 months (range, 3~102
months).
Statistical analysis
The short-term therapeutic effects of local tumor con-
trol were evaluated using direct method. The SPSS soft-
ware program (version 16.0; SPSS Inc, Chicago, IL) was
used for all statistical analyses. The Kaplan-Meier
method was used to evaluate the survival and local con-
trol rates. The survival and local control durations were
evaluated from the day of treatment. The log-rank test
was used to compare the different levels of a factor. Cox
Regression model was used for multivariate analysis of




The short-term effects of local control were evaluated at
four weeks after treatment finished. The CR rate in the
primary tumor was 18.60% (8/43), Also, The PR rate in
the primary tumor was 76.74% (33/43), 2 patients had
stable disease. None of the patients had progressive dis-
ease. The overall response rate (CR + PR) in the whole
study group was 95.35%.
Pattern of failure
The 1-, 2-, 3-, and 5-year local control rates (defined as
no progressive disease at the primary treatment site) in
all the patients were 77.54%, 53.02%, 39.77%, 15.46% (Fig-
ure 1), respectively. The 1-, 2-, 3-, and 5-year rates of
local control in those with Stage I disease were 91%, 75%,
58%, 44%, respectively, and 49%, 16%, 8%, 8%, respec-
tively, in those with Stage II disease (Figure 1, p =0 . 0 0 0 ) .
The 1- and 2-year local control rates were 75% and 60%
for tumor ≤3 cm; 84% and 71% for tumor sized 3~5 cm;
55% and 14.6% for tumor sized 5~7 cm; and 45%, 21% in
those with tumor size of >7 cm (Figure 2). 25 patients
had a local recurrence (Table 2). The median duration of
recurrence was 26 months (range, 3~91 months), 5 of 25
patients had a local recurrence over 36 months of treat-
ment. The rates of metastasis were 25%, 65%, 40%, 89%
in patients with tumor size of ≤3c m ,3 - 5c m ,5 - 7c m ,> 7
cm, respectively.
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The median survival time was 53 months (range, 3~102
months). The 1-, 2-, 3-, and 5-year rates of overall survi-
val in the whole group were 92.04%, 78.04%, 62.76%%,
42.61% (Figure 3), respectively. The 1-, 2-, 3-, and 5-
year overall survival rates in patients with Stage I disease
were 100%, 94%, 81%, 58%, respectively, and 82%, 55%,
37%, 24%, respectively, in patients with Stage II disease
(Figure 3, p = 0.005). Overall, 14 patients died: 3 died of
local recurrence, and 8 died of regional lymph node or
distant metastases. 2 died of systemic failure. 1 patient
with chronic obstructive pulmonary disease (COPD)
died of severe lung infection.
Patients with local recurrence, regional lymph node or
distant metastases had accepted the second SBRT
because the toxicity of the first SBRT was mild. 22 of 25
patients with local recurrence had the second SBRT.
After the treatment, 2 patients achieved CR; 15 patients
h a dP R ;4p a t i e n t sh a dS D ;a n d1p a t i e n th a dP D .T h e
overall response rate was 77.3%. Three patients didn’t
receive second SBRT, one of them received 2 cycles of
systemic combined chemotherapy with NVB and DDP.
One patient with one paratrachea lymph node metasta-
sis received SBRT. Five patients received SBRT of lung
metastases. One patient received SBRT for bilateral
adrenal metastases. The rest of patients with tumor pro-
gression were only given symptom relieving treatment
and supportive treatment.
Factors influencing outcome of treatment
The Univariate analysis showed that clinical stage and
tumor size had significant impact on local tumor control
(Table 3, 4) (p < 0.05); but multivariate analysis showed
only clinical stage had significant impact on local tumor
control (Table 5) (p < 0.05).
Univariate analysis (Table 3) and multivariate analysis
(Table 6) showed that both clinical stage and che-
motherapy were significant prognostic factors of overall
survival (p < 0.05).
Toxicity
The radiation-induced side effects of 43 patients after
SBRT were mild (Table 7), mostly grade 1~2, no grade
3 or above. None of the patients discontinued treatment
because of radiation toxicities.
Figure 1 The local control of patients with different stages.
Figure 2 The local control of patients with different tumor
sizes.
Table 2 the patterns of failure for tumor of different
sizes
Tumor size ≤3 cm 3~5 cm 5~7 cm >7 cm
Patients No. 4 20 10 9
Local recurrence 2 11 7 5
metastasis 1 13 4 8
Figure 3 The survival of patients with different stages.
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SBRT can improve cure rate of tumor and reduce radia-
tion-induced side effects by overcoming insufficiency of
conventional fractionated radiotherapy [21-24]. SBRT
can make sharp gradient of dose fall- off to improve
normal structure sparing and achieve highly conformal
dose distribution in tumor target by using 3D-planning
technique. Based on this technique, SBRT allows for
ablative doses to be delivered over a few fractions within
2 weeks. In recent years, SBRT has been widely used in
clinical practice and become a major treatment modality
for early stage NSCLC to obtain excellent outcome
[14,15,25-29].
In our study, most of patients had bulky lesions. The
local control was poor, especially for these with lesions
over 5 cm. Based on analysis of prognostic factors of
local tumor control in this study, both clinical stage and
tumor size were significant factors in Univariate analysis
(Table 3, 4) (p < 0.05); however, clinical stage was the
only significant prognostic factor in multivariate analysis
(Table 5) (p < 0.05). The pair wise comparisons of local
control in different tumor size demonstrated that local
Table 3 Univariate analysis of local tumor control and overall survival (log rank of Kaplan-Meier method)






Gender Male 32 1.054 0.305 2.671 0.102
Female 11
Age ≤70 23 0.832 0.362 0.116 0.733
>70 20
Karnofsky performance status 70 7 1.584 0.453 1.769 0.413
80 19
90 17
Comorbidities Yes 33 0.442 0.506 0.007 0.932
No 10
Type Central 8 0.427 0.514 0.173 0.678
Periphery 35




Clinical stage I 23 14.888 0.000 7.926 0.005
II 20






<6Gy 27 1.337 0.248 0.979 0.322
≥6Gy 16
BED (50% isodose line) <60Gy 17 0.550 0.458 0.033 0.856
≥60Gy 26
Chemotherapy no 30 2.194 0.139 6.000 0.014
yes 13
Abbreviation: BED: biological effective dose.
*: pairwise comparisons of local control of different size tumors.
Table 4 Pairwise comparisons of local control of different size tumors
Tumor size ≤3 cm 3~5 cm 5~7 cm >7 cm
Method Chi-Square Sig Chi-Square Sig Chi-Square Sig Chi-Square Sig
Log Rank (Mantel-Cox) ≤3 cm .002 .961 4.638 .031 .895 .344
3~5 cm .002 .961 10.977 .001 4.541 .033
5~7 cm 4.638 .031 10.977 .001 .108 .742
>7 cm .895 .344 4.541 .033 .108 .742
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cantly better than that of 5~7 cm and >7 cm (Table 4)
(p < 0.05). However, the local tumor control rate in
Xia’s study was 95% [2], better than that of our study.
In Xia’s study, 18 patients had tumor size ≤3c m ,2 1
had tumor size of 3~5 cm, and 4 had had tumor size >5
cm and with tumor BED value of 75 Gy (at 50% isodose
line). However, in our study, only 4 patients had tumor
size ≤3 cm, 20 patients had tumor size of 3~5 cm, and
19 patients had tumor size >5 cm; and the tumor mean
BED value was 62.86 Gy (range, 56~80 Gy, 50% isodose
line). It was considered that the percent of different size
tumors and tumor BED might explain the better local
tumor control rate of Xia’s study as compared to that of
our study. The BED at the isocenter (at 100% isodose
line) was high enough in this study; however, the local
control was poor, especially for those with lesions over
5 cm. Fakiris et al[25] had conducted a prospective
phase II trial of SBRT to treat 70 medically inoperable
NSCLC patients and achieved a 3-year local control of
88.1%. However, 50% of their patients had stage T1
lesions and none of their patients had tumor size larger
than 7 cm. Chi et al[26] had made a systemic review on
the patterns of failure following stereotactic body radia-
tion therapy in early stage non-small cell lung cancer; it
was found that tumor centre or periphery BED was
important parameter influencing local tumor control
rate and larger doses should be delivered for T2 tumor.
Therefore, more works needs to be done in future clini-
cal study to explore the optimal doses should be deliv-
ered for tumors of different size.
Based on the analysis of prognostic factors of overall
survival rate in this study, clinical stage and chemother-
apy were significant factorsi nm u l t i v a r i a t ea n a l y s i s
(Table 6) (p < 0.05). The mortality of the patients with
stage II was 4.064 times higher than that of the patients
with stageI (p = 0.015). Systemic chemotherapy increased
the risk of death of the patients with early stage NSCLC
in our study, the mortality of the patients with che-
motherapy was 3.659 times higher than that of the
patients without chemotherapy (p = 0.042). In these 13
patients receiving chemotherapy, the number of cases
with tumor size ≤ 3 cm, 3~5 cm, 5~7 cm, > 7 cm were 1
(7%), 5 (39%), 4 (31%), 3 (23%), respectively. Based on
our study, adjuvant chemotherapy may be helpful in the
setting of T3 lesions in some patients. The reason that
chemotherapy decreased the overall survival of the
patients in this study may be that most patients in this
cohort are elderly, with the mean age of 69 years. It’s
hard for them to recover from the influence of che-
motherapy like bone marrow suppression, gastrointest-
inal reaction and so on. So we think the patients for
adjuvant chemotherapy need to be carefully selected. The
patients with local tumor recurrence, or regional lymph
node, or distant metastasis were given second SBRT
because the radiation-induced side effects were mild. Siva
et al[30] reported the local tumor control rate of patients
with limited lung metastasis who received SBRT or SRS
were 77.9% or 78.6% in 2 years after treatment, respec-
tively; the toxicity was low, the rate of the toxicity above
grade 3 was 4% or 2.6%, respectively; the overall survival
rate was 53.7% or 50.3%, respectively. So the second SRT
could be the important prognostic factor of overall survi-
val rate in our study, which is worth further evaluating in
future clinical study.
I nt h i ss t u d y ,t h et o x i c i t y( T a b l e7 )w a sm i l d .N o
severe toxicity was observed during the whole treatment
process. This can be due to the low peripheral dose pre-
scribed in this study.
There were some limitations of our study. The dose
fractionation schedule used was not uniform, and tumor
motion is not well controlled without utilizing modern
4D CT to generate an IGTV based on MIP reconstruc-
tion. Also, the study is retrospective, and a prospective
study in the future will need to be conducted.
Conclusion
SBRT is an effective and safe therapy for patients with
medically inoperable early stage NSCLC. Clinical stage
was the significant prognostic factors for both local
tumor control and overall survival. The toxicity of SBRT
Table 5 Multivariate analysis of local tumor control (Cox
Regression method)
Factor B SE Wald df Sig. Exp(B) 95.0% CI for
Exp(B)
Lower Upper
Clinical stage 1.557 .444 12.323 1 .000 4.745 1.989 11.320
Table 6 Multivariate analysis of overall survival (Cox
Regression method)
factor B SE Wald df Sig. Exp(B) 95.0% CI for
Exp(B)
Lower Upper
Clinical stage 1.402 0.575 5.939 1 .015 4.064 1.316 12.553
Chemotherapy 1.297 .637 4.141 1 .042 3.659 1.049 12.760
Table 7 Radiation-induced side effects based on NCI-CTC
3.0 version.
Side effect Early No. Late No.
Grade Grade
123123
Pneumonitis 6 4 0 2 0 0
Esophagitis 3 4 0 0 0 0
Hematologic 8 2 0 0 0 0
Dermatitis 6 2 0 1 0 0
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poor. Tumor size is a poor prognostic factor, and the
patients for adjuvant chemotherapy need to be carefully
selected.
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